Lipid-Based Nanocarriers in the Management of Pulmonary Complications in Cystic Fibrosis

Code 35, the cystic fibrosis transmembrane conductance regulator (CFTR) causes respiratory failure, inflammation, and decreased airway mucociliary clearance. The absence of trustworthy preclinical models that replicate the anatomical, immunological, and bioelectrical characteristics of human CF lungs restricts the discovery of new therapies for the disease. Alternative carriers to liposomes, polymeric nanoparticles, and inorganic carriers include lipid-based nanocarriers (LBCs). Delivering medicines, nucleic acids, proteins, peptides, nutraceuticals, and cosmetics via LBCs has received more and more attention in recent years. Due to their simple production, physicochemical stability, and scalability, these nanocarriers have caught the attention of the industrial sector. Because of these qualities, LBCs are well suited for industrial manufacturing. Clinical trials are already being conducted on a number of LBC-containing items and are likely to swiftly grow in popularity. For commercial applications to produce enough formulations for clinical research, a large-scale manufacturing facility is necessary. The mainstay of treatment for CF, asthma, and chronic obstructive lung disease is the inhalation of corticosteroids and topical bronchodilators. These drugs are given through a metered-dose inhaler (MDI), a dry powder inhaler (DPI), a jet, or an ultrasonic nebulizer. Although the sheer number of gadgets may be overwhelming for patients and doctors, each has unique benefits.